anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Nonetheless, there have been sporadic reports of disturbances in the gastrointestinal flora of the infant, manifesting as diarrhea or oral candidiasis (thrush), associated with the use of β-lactam antibiotics, however, these potential side effects have not been thoroughly investigated specifically in the context of meropenem use, therefore, the safety profile of meropenem in breastfeeding mothers and their infants is unknown. Although meropenem is not approved for intramuscular or subcutaneous routes of administration in humans, there were studies that evaluated the drug bioavailability in cats and reported bioavailability of 99.69% for intramuscular route and 96.52 % for subcutaneous route of administration; these studies also compared elimination half-lives for intravenous, intramuscular or subcutaneous routes of administration in cats and reported duration of 1.35, 2.10 and 2.26 hours, respectively. There was also a small study on local tolerance of meropenem intramuscular administration in humans, and it was reported as generally good.
== Bibliography == Brown, M.S, Engelking, L.J, Evers, B, Goldstein, J.L, Hammer, R.E, Horton, J.D, Kuriyama, H, Liang, G, Li, W.P, & Liang, G 2005, 'Schoenheimer effect explained - Feedback regulation of cholesterol synthesis in mice mediated by Insig proteins', The Journal of clinical investigation, vol. 115, pp. 2489–98 Clarke, Hans T (12 December 1941). "Rudolf Schoenheimer, 1898-1941". Science, New Series. 94: 553–554. Cooper, D.Y, & Osborn, M.E 1999, 'Schoenheimer, Rudolph', American National Biography Helmenstine, A.M 2019, 'Deuterium Facts', https://www.thoughtco.com/facts-about-deuterium-607910 Engelking, L. J. (2005-08-25). "Schoenheimer effect explained - feedback regulation of cholesterol synthesis in mice mediated by Insig proteins". Journal of Clinical Investigation. 115 (9): 2489–2498. doi:10.1172/jci25614 ISSN 0021-9738. Fruton, Joseph S. (January 1982). "The carbobenzoxy method of peptide synthesis". Trends in Biochemical Sciences. 7 (1): 37–39. doi:10.1016/0968-0004(82)90064-0 ISSN 0968-0004. Hargrove, James L. (1998). Dynamic modeling in the health sciences. Springer. pp. ix. ISBN 0-387-94996-8. OCLC 876222114 Helmenstine, A.M (2019). "Deuterium Facts". Kohler R, Jr 1977, 'Rudolph Schoenheimer, Isotopic Tracers, and Biochemistry in the 1930s', Historical Studies in the Physical Sciences, vol. 8, pp. 257–298 Medawar, Jean: Pyke, David (2012). Hitler's Gift: The True Story of the Scientists Expelled by the Nazi Regime (Paperback). New York: Arcade Publishing. ISBN 978-1-61145-709-4.{{cite book}}: CS1 maint: multiple names: authors list (link) Quastel J.H.
==== Coffee ==== The world's primary source of caffeine is the coffee "bean" (the seed of the coffee plant), from which coffee is brewed. Caffeine content in coffee varies widely depending on the type of coffee bean and the method of preparation used; even beans within a given bush can show variations in concentration. In general, one serving of coffee ranges from 80 to 100 milligrams, for a single shot (30 milliliters) of arabica-variety espresso, to approximately 100–125 milligrams for a cup (120 milliliters) of drip coffee. Arabica coffee typically contains half the caffeine of the robusta variety. In general, dark-roast coffee has slightly less caffeine than lighter roasts because the roasting process reduces caffeine content of the bean by a small amount.
Samoyed dogs are most often white, and can have a brown tint to their double-layer coat, which is naturally dirt-repellent. They have been used in expeditions in both Arctic and Antarctic regions, and have a friendly and agreeable disposition.
Sources: en.wikipedia.org
Around 1500 BCE a tribe called the Oenotri ("vine-cultivators"), settled in the region. Ancient sources state they were Greeks who were led to the region by their king, Oenotrus. However it is more likely they were an ancient Italic people who spoke an Italic language. During the eighth and seventh centuries BCE, Greeks founded many settlements on the coast of southern Italy. In Calabria they founded Chone (Pallagorio), Cosentia (Cosenza), Clampetia (Amantea), Scyllaeum (Scilla), Sybaris (Sibari), Hipponion (Vibo Valentia), Epizephyrian Locris (Locri), Kaulon (Monasterace), Krimisa (Cirò Marina), Kroton (Crotone), Laüs (comune of Santa Maria del Cedro), Medma (Rosarno), Metauros (Gioia Tauro), Petelia (Strongoli), Rhégion (Reggio Calabria), Scylletium (Borgia), Temesa (Campora San Giovanni), Terina (Nocera Terinese), Pandosia (Acri) and Thurii, (Thurio, comune of Corigliano Calabro). In the year 744 BCE a group of Chalcidian settlers founded Rhegion (today Reggio Calabria) at the southern end of the peninsula. Soon after, other Chalcidans founded Zancle (current Messina) on the other side of the strait, securing their dominion over that arm of the sea. Later Chalcidian settlers from Rhegion and Zancle founded Metauros (Gioia Tauro) and divided the river of the same name (today Petrace) from the Italic city of the Tauri. In 710 BCE Ionian colonists founded Sybaris on the fertile plain of the same name at the mouth of the Crati.
On 23 January 2026, Danish prime minister Mette Frederiksen visited Greenland to express support for the people and the island's self-governing government, following comments by US president Donald Trump indicating his willingness to annex the territory. Trump had previously discussed strengthening security in the Arctic region with NATO secretary general Mark Rutte. Both the Danish and Greenlandic governments have affirmed that the island's sovereignty is indisputable, but remain open to discussions on issues such as security and economic development. The crisis eased after Trump withdrew threats of force and new tariffs.
== Chemistry == Do6a is the most abundant peptide in D. occidentalis venom with an EC50 of 113 nM which is much lower than that of other peptides in the same venom (for example, Do10a has an EC50 of 75 μM). The sequence of Do6a shares similarities in both amino acid composition and length to a known endogenous pain signaling peptide; Vulnusin. Vulnusin, which is present in Drosophila larvae, signals the larvae to initiate puncture-induced rolling as a defense strategy for moving away from parasitoid wasps. Compared to Do6a, Vulnusin has a significantly lower EC50, making it more potent. Nevertheless, there are speculations that velvet ants evolved venom peptides similar to vulnusin in order to target the same ion channel complex. Despite being the most potent and concentrated peptide in red velvet ant venom, Do6a alone does not appear to give rise to any considerable nocifensive responses in mice, such as paw licking. Even when administered at concentrations up to 10,000 higher than the EC50 for larval nociceptor activation, its effects in mice remain negligible. This indicates that the mode of action underlying Do6a-induced nociception differs between mammals and insects.
== Early life and background == Morea was born in Bangalore, Karnataka, to an Italian father and an Indian mother from Kalamassery, Kochi, Kerala. He spent the first eleven years of his life in Italy before returning to India. According to Morea, his name means "strong and powerful". He is the second of three brothers; his elder brother is Nicolò Morea and his younger brother is Santino Morea. Morea was educated at Bangalore Military School and Clarence High School, and later graduated from St. Joseph's College in Bangalore. While studying in college he represented India in U-13 tennis competition. He began modelling professionally and was subsequently offered his first acting role after being noticed during a fashion campaign.
=== X-rays === The discovery of X‑rays by Wilhelm Röntgen in 1895 led to widespread experimentation by scientists, physicians, and inventors. Many people began recounting stories of burns, hair loss and worse in technical journals as early as 1896. In February of that year, Professor Daniel and Dr. Dudley of Vanderbilt University performed an experiment involving X-raying Dudley's head that resulted in his hair loss. A report by Dr. H.D. Hawks, of his suffering severe hand and chest burns in an X-ray demonstration, was the first of many other reports in Electrical Review. Other experimenters, including Elihu Thomson and Nikola Tesla, also reported burns. Thomson deliberately exposed a finger to an X-ray tube over a period of time and suffered pain, swelling, and blistering. Other effects, including ultraviolet rays and ozone, were sometimes blamed for the damage, and many physicians still claimed that there were no effects from X-ray exposure at all. Despite this, there were some early systematic hazard investigations, and as early as 1902 William Herbert Rollins wrote almost despairingly that his warnings about the dangers involved in the careless use of X-rays were not being heeded, neither by industry nor by his colleagues. By this time, Rollins had proved that X-rays could kill experimental animals, could cause a pregnant guinea pig to abort, and that they could kill a foetus. He also stressed that "animals vary in susceptibility to the external action of X-light" and warned that these differences be considered when patients were treated by means of X-rays.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.